ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier

In brief

This phase I trial is studying the side effects and best dose of giving ABT-888 together with gemcitabine hydrochloride in treating patients with advanced solid tumors. ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with gemcitabine hydrochloride may kill more tumor cells.

Key facts

Study ID

NCT01154426

Run by

National Cancer Institute (NCI)

People needed

31

Starts

2010-05-01

Expected to finish

2013-10-01

Last updated by the study team

2015-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed solid tumors meeting 1 of the following criteria:
• Progressive disease following standard therapy
• Disease for which acceptable standard treatment options do not exist
• May have received 0-2 prior chemotherapeutic regimens (single-agent or combination chemotherapies)
• Willing to undergo BRCA mutation analysis
• Known BRCA mutations allowed
• All patients, at any dose level, without a known BRCA mutation undergo screening with the BRCAPRO program to assess the likelihood of having a BRCA mutation
• Patients with a BRCAPRO likelihood of gene mutation of ≥ 20% must undergo BRCA gene testing by the Myriad Genetic Laboratories in order to participate in the study
• Patients are eligible whether they have a known deleterious BRCA 1 or 2 mutation or a mutation of uncertain significance
• No CNS disease (e.g., brain metastases or glioma)
• No active seizure or history of seizure disorder
• ECOG performance status 0-2 (Karnofsky 60-100%)
• Life expectancy > 3 months
• ANC ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Bilirubin < 2.0 mg/dL
• AST and ALT < 3 times upper limit of normal
• Creatinine normal OR creatinine clearance > 50 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Able to swallow pills
• HIV-positive patients allowed provided that CD4 counts are < 500 and not on protease inhibitors
• No uncontrolled diarrhea
• No uncontrolled intercurrent illness including, but not limited to, any of the following:

Where it is running

• Penn State Milton S Hershey Medical Center — Hershey, Pennsylvania, United States
• UPMC-Magee Womens Hospital — Pittsburgh, Pennsylvania, United States
• University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania, United States
• University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.